岛津与美国Bioscan公司关于分子成像产品开展合作

　　岛津企业管理(中国)有限公司与美国Bioscan公司达成协议，于5月15日开始销售该公司的分子成像设备。

　　分子成像设备是通过对实验小动物(小鼠，裸鼠)注射分子探针，从而反应目标活体机能或和目标分子进行结合。并通过图像阐明疾病发生机理，加速新药开发。

　　美国Bioscan公司是分子成像设备的专业厂商，在欧美占有很高的市场份额。通过此次强强联手，岛津企业管理(中国)有限公司将通过销售Bioscan的产品进入中国的分子成像市场，以便为客户提供高品质的产品及相关服务。

岛津中国·古泽社长与Bioscan公司Staf van Cauter总裁合影

　　自本月起，岛津开始销售以下Bioscan分子成像产品。

　　实验小动物用荧光断层装置

　　BioFLECT

　　BioFLECT/CT

　　实验小动物用核磁共振成像装置(MRI)

　　MRS 1500

　　MRS 3000

　　随着合作深入，双方将不断加强更多产品的合作。

　　此次合作的产品系列中，实验小动物用荧光断层装置BioFLECT，BioFLECT/CT(注1)

　　(FLuorescence Emission Computed Tomography)

　　作为小动物用光成像设备，是世界上第一台可以360°断层扫描的设备。

　　实验小动物用光成像作为活体分子探针成像设备(体内成像设备)的一种，被广泛应用于生命科学领域。

　　以往的光成像设备很难得到活体的深部信息，体内成像很难得到解剖学的位置信息。BioFLECT通过360°的荧光断层扫描，可以得到高分辨率的荧光断层图像。

　　BioFLECT/CT 在BioFLECT上配备了一体型X射线CT，可以得到X射线图像和荧光断层图像相融合的精确图像。

实验小动物用核磁共振成像设备MRS 1500(1.5特斯拉)，MRS 3000(3特斯拉)

　　MRS系列尽管使用超导磁体，紧凑机身设计无需液氮制冷、无需屏蔽设施即可进行检测的MRI设备。

　　生命维持系统(Minerve系统)可通用于Bioscan公司其他活体成像设备上，因此将小动物固定于生命维持架上，便可在Bioscan其他设备上进行成像观察。

         英文原稿：

　　Shimadzu Corporation Agrees to Represent Bioscan Molecular Imaging Products in China

　　Washington, DC, USA and Shanghai, China - May 28, 2013 – Earlier this month, Shimadzu Enterprise Management (China) Co., Ltd. (“Shimadzu”) andBioscan, Inc. (“Bioscan”) reached an agreement enabling Shimadzu to distribute Bioscan’s molecular imaging products in China. Shimadzu began representing the Bioscan product line on May 15th.

　　Preclinical molecular imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant, consistent biological data while reducing research cost and complexity. The result is more efficient, effective research into disease characteristics, new diagnostics and new therapies.

　　Washington, DC-based Bioscan is a well-established supplier of molecular imaging devices, with a strong market share in Europe and North America. Through its partnership with Bioscan, Shimadzu Enterprise Management (China) Co., Ltd. will provide Chinese research customers with high quality products and related services.

　　Caption: Mr. Furusawa, President of Shimadzu China and Staf van Cauter, President and CEO of Bioscan shake hands after concluding the distribution agreement

　　Shimadzu will be focusing on several of Bioscan’s molecular imaging products:

　　· BioFLECT and BioFLECT/CT small animal true-360° fluorescence tomography scanners

　　· MRS 1500 and MRS 3000 small animal molecular magnetic resonance imaging (MRI) scanners

　　· BioPET/MR combination positron emission tomography (PET) and MRI scanners

　　The two companies plan to extend the collaboration to more products over time.

　　With the new BioFLECT (FLuorescence Emission Computed Tomography) scanner, Bioscan enables researchers to realize the full potential of in vivo optical imaging for the first time. With BioFLECT's true 360° tomographic system, researchers no longer have to choose between imaging only near the surface of the subject and partial tomography solutions that distort the subject or create artifacts. Instead, the BioFLECT provides uniform sensitivity and resolution throughout the subject. For the first time, researchers will be able to examine deep tissue phenomena such as spontaneous metastases without sacrificing image quality or quantitative accuracy. With the optional upgrade to integrated, inline X-Ray CT, researchers will gain anatomical correlation data that will significantly improve the segmentation and resolution of the optical image.

　　Caption: Bioscan’sBioFLECT/CT (FLuorescenceEmission Computed Tomography) Scanner.

　　Bioscan’spreclinical molecular MRI systems, the MRS 1500 (1.5T) & MRS 3000 (3.0T), rely upon innovative, cryogen-free superconducting magnets that have virtually no fringe field, enabling safe use of the system in any facility and by any operator. Designed to work withBioscan'smolecular imaging modalities (PET, SPECT and FLECT), these MRI systems deliver powerful performance and ease-of-use. The MRS 1500 and MRS 3000 systems are compact with a small footprint design and can be placed within 1-2m of another imaging system.

　　All Bioscan systems utilize common animal handling and image analysis solutions, enabling multimodality use with other Bioscan systems.

　　About Bioscan

　　Bioscan is a leading supplier of preclinical, nano-tomographic molecular imaging solutions that enable groundbreaking life sciences research. Preclinical imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant, consistent biological data while reducing research cost and complexity. Bioscan’s innovative nuclear (PET & SPECT), 3D optical, ultrasound, X-Ray CT and MRI imaging tools are used by more than 100 leading academic and government research institutions and life sciences companies worldwide to improve their disease, drug discovery and development research. The unique imaging performance enabled by Bioscan‘s patented technologies makes it possible to translate research protocols and results directly from animal models of diseases to human clinical trials, enabling faster, more efficient development of new diagnostics and therapies. Bioscan is a privately held company based in Washington, DC, USA. www.bioscan.com

　　关于岛津

　　岛津企业管理(中国)有限公司是(株)岛津制作所为扩大中国事业的规模，于1999年100%出资，在中国设立的现地法人公司。

　　目前，岛津企业管理(中国)有限公司在中国全境拥有13个分公司，事业规模正在不断扩大。其下设有北京、上海、广州、沈阳、成都分析中心;覆盖全国30个省的销售代理商网络;60多个技术服务站，构筑起为广大用户提供良好服务的完整体系。

　　岛津作为全球化的生产基地，已构筑起了不仅面向中国客户，同时也面向全世界的产品生产、供应体系，并力图构建起一个符合中国市场要求的产品生产体制。 以“为了人类和地球的健康”为目标，岛津人将始终致力于为用户提供更加先进的产品和更加满意的服务。

　　更多信息请关注岛津公司网站www.shimadzu.com.cn/an/ 。